Related Experiment Video

Updated: May 30, 2026

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures
08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells

Mary E Irwin1, Natacha Bohin, Julie L Boerner

  • 1Department of Pharmacology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.

Cancer Biology & Therapy
|July 22, 2011
PubMed

Insights

Epidermal growth factor receptor (EGFR) and c-Src kinase signaling in lipid rafts promote breast cancer cell survival. Inhibiting both EGFR and Src synergistically reduces cell viability by blocking Akt activation.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Epidermal growth factor receptor (EGFR) activation is crucial for breast cancer cell proliferation, survival, and migration.
  • EGFR signaling is initiated at the cell membrane but also occurs at other cellular locations.
  • EGFR's role in triple-negative breast cancer (TNBC) cell lines involves lipid raft localization, promoting Akt activation independently of its kinase activity.

Purpose of the Study:

  • To elucidate the mechanism by which lipid rafts regulate EGFR signaling to Akt in breast cancer.
  • To investigate the role of non-receptor tyrosine kinase c-Src in EGFR-mediated signaling within lipid rafts.
  • To evaluate the therapeutic potential of combined EGFR and Src inhibition in resistant breast cancer cells.

Main Methods:

  • Co-localization and co-association studies of EGFR, c-Src, and PI3K within lipid rafts.
  • Assessment of Akt phosphorylation levels in response to EGFR and Src inhibition.
  • Evaluation of cell viability upon combined EGFR and Src family kinase (SFK) inhibitor treatment.

Main Results:

  • Non-receptor tyrosine kinase c-Src co-localizes and associates with EGFR and lipid rafts.
  • Breast cancer cells resistant to EGFR inhibitors were also resistant to SFK inhibitors.
  • Combined EGFR and SFK inhibition synergistically decreased cell viability, correlating with reduced Akt phosphorylation.
  • Phospho-inositide 3 kinase (PI3K) associated with lipid rafts when EGFR and c-Src were co-localized.

Conclusions:

  • Lipid rafts serve as a signaling platform for EGFR, c-Src, and PI3K interactions.
  • This platform facilitates the activation of pro-survival signaling pathways in breast cancer cells.
  • Targeting both EGFR and c-Src simultaneously offers a promising therapeutic strategy for overcoming resistance in breast cancer.

More Related Videos

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development09:32

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development

Published on: June 15, 2017

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...